Effect of monophosphoryl lipid A (MPL ( R)) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM 197 conjugate vaccine in healthy toddlers

Author： Vernacchio L.   Bernstein H.   Pelton S.   Allen C.   MacDonald K.   Dunn J.   Duncan D.D.   Tsao G.   LaPosta V.   Eldridge J.   Laussucq S.   Ambrosino D.M.   Molrine D.C.  

Publisher： Elsevier

ISSN： 0264-410X

Source： Vaccine, Vol.20, Iss.31, 2002-11, pp. : 3658-3667

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL ( R)) adjuvant: a new allergy vaccine for dust mite allergy

By Baldrick P.   Richardson D.   Wheeler A.W.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 737-743

Elsevier

Access to resources Recommend Favorite

DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL(R))

By Lodmell D.L.   Ray N.B.   Ulrich J.T.   Ewalt L.C.  

Vaccine, Vol. 18, Iss. 11, 2000-01 ,pp. : 1059-1066

Elsevier

Access to resources Recommend Favorite

Immunogenicity of anti-Haemophilus influenzae type b CRM 197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant

By Mariotti S.   Teloni R.   von Hunolstein C.   Romagnoli G.   Orefici G.   Nisini R.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2229-2239

Elsevier

Access to resources Recommend Favorite

Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM 197 conjugate vaccines

By Bolgiano B.   Mawas F.   Yost S.E.   Crane D.T.   Lemercinier X.   Corbel M.J.  

Vaccine, Vol. 19, Iss. 23, 2001-04 ,pp. : 3189-3200

Elsevier

Access to resources Recommend Favorite

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL ( R) adjuvant

By Skeiky Y.A.W.   Coler R.N.   Brannon M.   Stromberg E.   Greeson K.   Thomas Crane R.   Campos-Neto A.   Reed S.G.  

Vaccine, Vol. 20, Iss. 27, 2002-09 ,pp. : 3292-3303

Elsevier

Access to resources Recommend Favorite